Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195260 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
NCT00195260 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 151 participants.
The verdict
NCT00195260, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of oral SKI-606 (bosutinib) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population.
Interventions
- DRUG bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195260
The ClinicalTrials.gov registry entry for NCT00195260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bosutinib is the first listed.
NCT00195260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195260 about?
NCT00195260 is a clinical study titled "Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors". To evaluate the safety and tolerability of oral SKI-606 (bosutinib) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population.
What is the current status of trial NCT00195260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2004-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00195260?
The interventions under investigation include: bosutinib (DRUG).
Who is sponsoring clinical trial NCT00195260?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.